Aisling Capital Management LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 10, 2026), Aisling Capital Management LP reported 13 stock positions worth $478.9 million. Its top holding was Bridgebio Pharma (BBIO) at 81.3% of the portfolio, followed by Syndax Pharmaceuticals (SNDX, 5.8%) and Monte Rosa Therapeutics (GLUE, 4.8%). Compared with Q3 2025, it opened 1 new position, sold out of 2 and reduced 1. The biggest buy was a new position in Urogen Pharma (URGN) and the biggest sale an exit from Verona Pharma (VRNA).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001766721
- Portfolio Value
- $478.9M (Q4 2025)
- SEC Filing
- 0001766721-26-000001 ↗ filed Feb 10, 2026
Holdings Value
Holdings 13 stocks · $478.9M
| BBIO Bridgebio Pharma Inc. | 81.29% | 5,089,611 | $389.3M | Reduce -16.4% |
| SNDX Syndax Pharmaceuticals Inc. | 5.78% | 1,316,806 | $27.7M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 4.82% | 1,472,331 | $23.1M | No change |
| BCAX Bicara Therapeutics Inc. | 2.00% | 568,919 | $9.6M | No change |
| CMPS Compass Pathways PLC | 1.73% | 1,198,418 | $8.3M | No change |
| BBOT Bridgebio Oncology Therapeut | 1.48% | 564,625 | $7.1M | No change |
| CALC Calcimedica Inc. | 0.72% | 521,114 | $3.4M | No change |
| SRRK Scholar Rock Holding Corp. | 0.71% | 77,031 | $3.4M | No change |
| BMEA Biomea Fusion Inc. | 0.53% | 2,048,757 | $2.5M | No change |
| URGN Urogen Pharma Ltd. | 0.53% | 108,000 | $2.5M | New |
| ACRS Aclaris Therapeutics Inc. | 0.27% | 434,455 | $1.3M | No change |
| MRKR Marker Therapeutics Inc. | 0.10% | 325,370 | $485K | No change |
| OKUR Onkure Therapeutics Inc. Class A | 0.05% | 88,607 | $257K | No change |
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
| URGN Urogen Pharma Ltd. | New | 0.53% | +0.53 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $471.6M | BBIO, GLUE, SNDX, CMPS, BCAX |
| Q1 2026 | 13 | $476.3M | BBIO, SNDX, GLUE, BCAX, BBOT |
| Q4 2025 | 13 | $478.9M | BBIO, SNDX, GLUE, BCAX, CMPS |
| Q3 2025 | 14 | $456.4M | BBIO, VRNA, SNDX, NUVB, GLUE |
| Q2 2025 | 13 | $359.7M | BBIO, VRNA, SNDX, GLUE, BCAX |
| Q1 2025 | 13 | $288.5M | BBIO, VRNA, SNDX, BCAX, GLUE |
| Q4 2024 | 15 | $281.8M | BBIO, VRNA, SNDX, GLUE, PSTX |
| Q3 2024 | 16 | $261.1M | BBIO, VRNA, SNDX, BCAX, BMEA |
| Q2 2024 | 15 | $231.1M | BBIO, SNDX, VRNA, ELEV, NUVB |
| Q1 2024 | 16 | $295.5M | BBIO, SNDX, VRNA, ELEV, BMEA |